Loading stock data…
LLY
$1144.68-4.47 (-0.39%)
After Hours$1145.00+0.32 (+0.03%)· Last close Jun 9
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eli Lilly and Company in the Healthcare sector is trading at $1,143.12 with a market capitalization of $928.9B. Wall Street consensus targets $1,215.10 (29 analysts), implying a +6.3% move over the next 12 months. The stock is currently near its 52-week high of $1,182.73, remaining 20.4% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1144.68
Potential Upside
61.8%
Whystock Fair Value$1852.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus29 analysts
Buy
Mean target$1215+6.2%
Range$850.00 – $1500
Fundamentals
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$928.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
37.04
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.41%
ROE
Elite ROE. Management converts capital into profit efficiently.
81.02%
Volume
Today's trading volume
3.72M
Recent News
Dow Jones AI Giant Nvidia Stock Tumbles To Key Support Level Amid Market Sell-Off
Dow Jones AI giant Nvidia stock tumbled to a key support level during Tuesday's stock market sell-off. A decisive bounce would be bullish.
Eli Lilly Expands Alzheimer’s Pipeline With AlzeCure Deal And Valuation Upside
Eli Lilly (NYSE:LLY) has entered a collaboration and licensing agreement with AlzeCure Pharma for global rights to Alzstatin ACD680, a preclinical Alzheimer's therapy. The deal structure includes potential payments that could exceed US$1b if development, regulatory and commercial milestones are reached. The agreement expands Lilly's neuroscience and Alzheimer's disease pipeline beyond its existing focus on obesity and metabolic treatments. Eli Lilly is best known today for its obesity and...
Prediction: Eli Lilly Will Trade at This Price in a Year
Eli Lilly (NYSE:LLY) is finally acting like a trillion-dollar drugmaker again. After a brutal stretch in late 2025 and a wobbly start to this year, the stock punched through fresh 52-week highs on retatrutide Phase 3 data that analysts call potentially first-line for obesity. The stock trades at $1,149.15 with a one-year gain of 50.31%, ... Prediction: Eli Lilly Will Trade at This Price in a Year
Lilly Makes a New Alzheimer's Pipeline Move
AlzeCure Deal Expands Lilly's Neuroscience Pipeline Early
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.